Amneal highlights positive topline results from confirmatory clinical study of biosimilar candidate to xolair(r) (omalizumab), developed by kashiv biosciences

Amneal holds exclusive u.s. commercialization rights; bla filing expected in q4 2025 poised to be among the first wave of biosimilars in the $3.9 billion u.s. omalizumab market and an important growth driver for amneal bridgewater, n.j., june 25, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating adl-018, a proposed biosimilar to xolair® (omalizumab), developed by kashiv biosciences, llc.
AMRX Ratings Summary
AMRX Quant Ranking